Literature DB >> 11298144

Uptake and intracellular activity of ketolide HMR 3647 in human phagocytic and non-phagocytic cells.

S Ballesta, I García, E J Perea.   

Abstract

OBJECTIVE: To evaluate the uptake of HMR 3647 into human neutrophils (PMNs), human peritoneal macrophages (PMOs) and tissue-cultured cells (epithelial cells and fibroblasts), and to assess the intracellular activity of this drug.
METHOD: Cell uptake of HMR 3647 was measured by radiometric assay, as described by Klemper and Styrt. Intracellular activity was determined by incubation for 3 h of PMNs containing bacteria in the presence of HMR 3647.
RESULTS: The intracellular concentrations were 130 and 71 times higher than extracellular concentrations in PMNs and PMOs, respectively (extracellular concentrations: 2-25 mg/L). The cellular-to-extracellular concentration ratios (C/E) for tissue-cultured cells were lower than those obtained in phagocytic cells but still greater than 5. The uptake of HMR 3647 was rapid and non-saturable in all cells. HMR 3647 was released slowly from phagocytic cells. HMR 3647 (extracellular concentration: 0.5-10 mg/L) did not significantly reduce the intracellular survival rate of Staphylococcus aureus ATCC 25923 in PMNs.
CONCLUSIONS: HMR 3647 reaches intracellular concentrations several times higher than extracellular concentrations within phagocytic and non-phagocytic cells. The slow efflux of this drug from phagocytic cells suggests that these cells may be a vehicle for it, delivering it to sites of infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11298144     DOI: 10.1046/j.1469-0691.2001.00213.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  8 in total

1.  Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin.

Authors:  Martina Bosnar; Zeljko Kelnerić; Vesna Munić; Vesna Eraković; Michael J Parnham
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

2.  Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages.

Authors:  Cristina Seral; Jean-Michel Michot; Hugues Chanteux; Marie-Paule Mingeot-Leclercq; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

3.  Comparative activities of antibiotics against intracellular non-typeable Haemophilus influenzae.

Authors:  Christina Kratzer; Wolfgang Graninger; Karin Macfelda; Astrid Buxbaum; Apostolos Georgopoulos
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 4.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 5.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.

Authors:  Cristina Seral; Françoise Van Bambeke; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 7.  Intracellular Penetration and Effects of Antibiotics on Staphylococcus aureus Inside Human Neutrophils: A Comprehensive Review.

Authors:  Suzanne Bongers; Pien Hellebrekers; Luke P H Leenen; Leo Koenderman; Falco Hietbrink
Journal:  Antibiotics (Basel)       Date:  2019-05-04

8.  Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.

Authors:  Lionel A Mandell; John G Bartlett; Scott F Dowell; Thomas M File; Daniel M Musher; Cynthia Whitney
Journal:  Clin Infect Dis       Date:  2003-11-03       Impact factor: 9.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.